According to this article, pharma companies that are eyeing global markets as an afterthought to U.S. and developed markets are losing out on major opportunities that come from thinking globally in the first place. Due to the extent of innovation coming out of some Asian pharmaceutical companies, the connection with a large U.S. pharma company won't even be necessary.